Forensic Analysis · Industrials / Manufacturing / Defense · as of Aug 11, 2026

Eyepoint, Inc. (EYPT)

A forensic read on Eyepoint, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

D · Weak — demands caution

Forensic grade

Grey Zone

Financial health

3.5

Distress distance

Clean

Earnings quality

Forensic signals

-3.7

P / E (ttm)

-75.8%

ROE

$1.1B

Market cap

0.00%

Dividend yield

-27.5%

Revenue growth

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Eyepoint, Inc. earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads 3.5, placing it in the Grey zone. 2 forensic signals were flagged in its latest SEC filings, led by share-count dilution.

What the filings flag

+25.2%/yr

FY2022–FY2025

Share-count dilution. Diluted share count changed +96% over the last 3 years to FY2025 (+25.2%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~25.2% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~49%.

89% of rev

FY2025

Stock-based comp load. Stock-based compensation ran 89% of revenue in FY2025. The cost of it is not in the cash flow — no cash left the business — it is in the count: holders gave up about 26.4% of the company a year, and that rate is not falling. That is the figure to weigh, not the share of free cash flow.

Key fundamentals

Latest Revenue$31.4M

Revenue Growth YoY-27.5%

Net Margin-739.4%

Free Cash Flow-$243.4M

Return on Equity-75.8%

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Eyepoint, Inc.'s actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Aug 11, 2026. Forensic signals flag probability, not certainty.